Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

J&J's Velcade cleared by U.K. for first-line myeloma treatment in about-face

The U.K.'s National Institute for Health and Care Excellence has come around on Johnson & Johnson's Velcade as a first-line treatment for the blood cancer multiple myeloma. It approved the drug for the new use today, four months after initially saying it was unconvinced the benefits of the drug outweighed its costs.

Arkansas court boots $1.2B J&J verdict on technical grounds

In defending the largest state-level decision ever won against Johnson & Johnson for its Risperdal marketing, the state of Arkansas said the New-Jersey based company didn't properly communicate the antipsychotic's risks and marketed it for off-label use. In its appeal, J&J said it didn't commit fraud or harm the state's Medicaid program. But Arkansas' Supreme Court had something entirely different to say when it overturned the $1.2 billion judgment Thursday.

J&J blazes a new pharma trail with industry's first designer-in-chief

Johnson & Johnson has designs on a brand-new way of thinking about products. The company is hiring a chief design officer, The Wall Street Journal reports, to create drugs and consumer products that look good, work well, and--it hopes--sell better.

J&J trumpets early success for 3-month Invega Sustenna PhIII schizophrenia trial

J&J wrapped a Phase III study of a 3-month formulation of Invega Sustenna early after an independent monitoring group called it on positive efficacy data. That's good news for J&J as well as Alkermes, which provided their NanoCrystal delivery tech for the new-and-improved therapy.

Don't bet on a home-run drug launch, even for power-hitting drugs

Two-thirds of new drugs fall short of expectations their first year on the market and continue to fall short after that. But McKinsey & Co. consultants found that good launches are very, very good. What makes the difference? The consulting firm took a close look at 60 different drug launches to find out.

McKinsey's 4 drug launch flavors: Good, bad, ugly and misguided

What's the probability of a good drug launch? About one in three, according to a new McKinsey & Co. analysis. And if a launch is good, it tends to be very, very good, beating forecasts year after year.

J&J's $2.5B-plus metal hip settlement offer approaches April 1 deadline

Patients have until April 1 to decide whether to sign on to the $2.5 billion-plus agreement Johnson & Johnson proposed last November to resolve 8,000 patient lawsuits involving defective all-metal hip implants. It's not clear yet whether the conglomerate will draw in enough people so the settlement can move forward.

J&J, Pharmacyclics and the future of Big Pharma dealmaking

Eventual winner Johnson & Johnson wasn't Pharmacyclics' first choice to partner with on ibrutinib, CEO Robert Duggan told FierceBiotech in January, but, as The Wall Street Journal lays out, J&J and its expansive approach to dealmaking won out in the end.

GlaxoSmithKline's FDA batting average tops the industry; Lilly, not so much

Reaping the benefits of deep-seated R&D reorganization, GlaxoSmithKline had the industry's best 6-year run of FDA nods for new drugs, according to EvaluatePharma, leading its competitors by a wide margin and leaving approval-starved outfits like Eli Lilly and Merck in the dust.

In SGLT2 diabetes fight, Lilly's empagliflozin loss is J&J and AstraZeneca's gain

Johnson & Johnson and AstraZeneca will just have to duke it out for share of the market for SGLT2 treatments for diabetes. A potential third competitor from Eli Lilly and Boehringer Ingelheim, empagliflozin, failed to win FDA approval, thanks to problems at a Boehringer manufacturing plant.